Ironwood's LINZESS drives record growth despite U.S. stock market pressures

Ironwood Pharmaceuticals has reported strong financial and operational results for 2025, driven largely by its flagship product, LINZESS. The drug maintained steady demand growth, treating over 5.7 million patients since its launch, while the company cut costs and boosted cash reserves to $250 million by year-end.

The outlook for 2026 remains positive, with projected LINZESS sales exceeding $1.1 billion—a jump of over 30% from the previous year.

LINZESS continued its upward trajectory in 2025, securing an 11% rise in prescription demand for the second year running. New patient uptake contributed an 8% increase in brand volume, reinforcing its dominance in the U.S. stock market. By the end of the year, the drug held a 45% share of prescriptions for irritable bowel syndrome with constipation (IBS-C) and chronic constipation.

Financial performance reflected both growth and efficiency. U.S. net sales reached $865 million, though this marked a 6% dip from 2024 due to Medicare Part D pricing pressures. Despite this, Ironwood generated $127 million in operating cash flow and slashed expenses by $61 million through tighter cost controls. Adjusted EBITDA came in at $138 million, with forecasts predicting it will more than double to over $300 million in 2026.

Expansion into new markets has faced hurdles. While the FDA approved LINZESS for paediatric use in November 2025, its European growth remains stalled. Without European Medicines Agency (EMA) approval, the drug relies on partnerships like the one with AbbVie, yet no significant market gains have been reported in early 2026.

Ironwood enters 2026 with a strong financial footing, backed by $250 million in cash and a projected 30% surge in LINZESS sales. The drug's U.S. market leadership contrasts with slower progress in Europe, where regulatory barriers persist. With disciplined cost management and rising demand, the company aims to build on its 2025 performance in the year ahead.